European Innovation Council

The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.

David Malo Jean

Director

Past deals in Early Venture Stage

Chipiron

Series A in 2025
Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Astrape Networks

Grant in 2025
Astrape powers the future of datacenters: more bandwidth, less power.

Sparrow Quantum

Series A in 2025
Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

QuantWare

Series A in 2025
QuantWare is a leading provider of quantum hardware, specializing in scalable quantum processors designed to enhance computational capabilities. The company has developed the VIO QPU scaling technology, which serves as a platform for various qubit designs, facilitating the development of quantum computers with the potential to exceed one million qubits. QuantWare operates under the Quantum Open Architecture paradigm, supplying fully packaged quantum processing units (QPUs) and offering Foundry and Packaging Services to clients in 20 countries across four continents. Its innovative 3D-dimensional chip architecture enables customers to build connected and scalable quantum systems, aimed at addressing complex challenges in fields such as climate and life sciences.

PrecisionLife

Grant in 2025
PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Stablepharma

Grant in 2025
Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

MOA

Grant in 2025
MOA make healthy food for a sustainable world that solves growing global food demands. They are establishing a new industry of sustainable food that solves growing global food demands without the need for arable land. They are focused on designing high-value, natural and nutritious food.

Deeploy

Grant in 2025
Deeploy is a developer of a machine learning operations platform focused on enhancing the accountability and transparency of AI systems. The platform centralizes explainable AI (XAI) within machine learning operations (MLOps), empowering users to comprehend how models function and to rectify automated decisions when necessary. By organizing deployments, tracking model performance, generating trace logs, and facilitating the creation of custom models and explainers, Deeploy provides data scientists and users with the tools needed to understand the implications and applications of machine learning models. This approach ensures that AI systems are both trustworthy and accountable.

QDI systems

Grant in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

AlzeCure Pharma

Grant in 2025
AlzeCure Pharma AB, established in 2012 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to developing drug therapies for central nervous system disorders. The company's primary focus is on Alzheimer's disease, with a pipeline consisting of five drug candidates based on its NeuroRestore and Alzstatin research platforms. These candidates are in various stages of development, targeting conditions such as sleep disruptions, traumatic brain injuries, neuropathic pain, and eye/ear indications. AlzeCure's team comprises key professionals with complementary expertise, spanning from molecule to man, and the company aims to be an industry-standard incubator for novel projects.

Elicera Therapeutics

Grant in 2025
Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

TENSIVE

Series A in 2025
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Photon IP

Grant in 2025
Photon IP is a deeptech startup located in Eindhoven, the Netherlands, focused on developing advanced technologies for photonics applications. The company specializes in application-specific semiconductors that cater to various sectors, including wearable electronics and data centers. By providing innovative solutions, Photon IP supports clients in industries such as automotive and telecommunications, aiming to enhance the functionality and efficiency of their products.

AQLAS

Grant in 2025
AQLAS is shaping the quantum future and discovering Next-Gen Lasers redefining quantum computing. Our high-quality hardware is set apart by its economical, compact, and efficient nature, thus paving the way for the proliferation of quantum computers.

Hervolution Therapeutics

Series A in 2024
Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.

ION-X

Series A in 2024
ION-X is a technology developer focused on creating efficient propulsion systems for small spacecraft, particularly in the satellite sector. The company specializes in electric propulsion that utilizes the ejection of finely ionized particles, achieving high thrust and specific impulse (ISP). This innovative approach offers a long operational lifespan, high modularity, and cost-effective production capabilities, making it suitable for mass production. ION-X aims to support the expanding aerospace market by providing advanced thruster solutions that meet the increasing demand for efficient and reliable propulsion technologies.

Onward

Grant in 2024
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

AISPECO

Grant in 2024
AISPECO is a Lithuanian company that specializes in geospatial monitoring systems for various types of vehicles, including helicopters, planes, unmanned aerial vehicles (UAVs), and terrestrial vehicles. The company develops aerial inspection systems specifically designed for conducting powerline surveys using helicopters and drones. Its platform is capable of capturing multiple types of imagery, such as optical, infrared, corona, and hyperspectral, which enhances the efficiency and effectiveness of infrastructure inspections. By focusing on advanced imaging technology, AISPECO enables clients to perform inspections with greater endurance and scalability in their operations.

Quantune Technologies

Grant in 2024
Quantune is a deep tech startup specializing in optics and photonics technology. The company develops a compact infrared spectrometer that miniaturizes traditional laboratory equipment for molecular analysis, making it accessible for both biomedical consumer devices and industrial applications. This innovative spectrometer facilitates continuous and non-invasive health monitoring, allowing clients to achieve real-time monitoring and analysis of chemical compounds and emissions. By transforming large-scale laboratory processes into a portable module, Quantune enables novel applications in various fields, enhancing the capabilities of health and environmental monitoring.

Turing College

Grant in 2024
Turing College operates as an online educational institution specializing in data science. It offers courses suitable for individuals of varying skill levels and employs an income share agreement model, allowing students to defer payment until they secure employment. The college collaborates with tech companies to co-create its curriculum, providing these partners with real-time student performance updates to facilitate expedited hiring decisions.

National University of Ireland, Maynooth

Grant in 2024
Maynooth University is internationally recognised for quality and value of Their research and scholarship and Their dedication and commitment to teaching and Their students. Part of the NUI and formally established as an autonomous university in 1997, Maynooth University traces its origins to the foundation of the Royal College of St. Patrick in 1795, drawing inspiration from a heritage that includes over 200 years of education and scholarship. The University is a place of lively contrasts. It is a modern institution, dynamic, rapidly-growing, research-led and engaged, yet grounded in historic academic strengths and scholarly traditions.

Hideez

Grant in 2024
Hideez is a cybersecurity company that specializes in manufacturing hardware and providing services for secure authentication. Based in the USA and Ukraine, the company offers the Hideez Key, a hybrid device combining wireless authentication, password management, and access control for both physical and digital environments. This multifunctional key uses encrypted Bluetooth, RFID, and NFC technologies, and supports various authentication standards, making it a versatile and secure solution for managing user credentials.

Sequentia Biotech

Series A in 2024
Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Ephos

Grant in 2024
Ephos specializes in the development of integrated photonic circuits utilizing glass technology to improve computing capabilities. The company aims to minimize signal loss, facilitating innovative designs for both classical and quantum applications. By employing a proprietary manufacturing process, Ephos produces high-quality circuits tailored to the specific requirements of clients in the computational infrastructure sector. Their products are particularly suited for use in quantum computing, quantum communications, and quantum sensing, enabling customers to create scalable quantum infrastructures.

Reverion

Series A in 2024
Reverion specializes in developing reversible, carbon-negative power plants that leverage patented technology to maximize the potential of biogas. The company's containerized units, designed for mass production, achieve remarkable electrical efficiencies of 80% for both power generation and energy storage. This innovative approach not only doubles the electricity output of traditional gas engines but also significantly reduces greenhouse gas emissions, resulting in a negative CO2 balance. Additionally, Reverion's technology is capable of utilizing excess solar and wind power, enhancing electricity production in existing biogas plants and stabilizing the power grid during electrolysis. Through these advancements, Reverion aims to promote a renewable and decarbonized energy future.

Treble

Series A in 2024
Treble Technologies develops advanced wave-based sound simulation products tailored for the architecture, engineering, and construction (AEC) industry. The company specializes in acoustics design software that enables the creation of visually accurate and realistic virtual acoustics. By streamlining the processes of importing, exporting, and reconfiguring models, Treble's solutions help reduce risk and ensure that designs meet regulatory and certification requirements. Their technology is applied across various sectors, including automotive, building design, immersive reality, and artificial intelligence. Through its innovative platform, Treble empowers studios and artists to lower costs, mitigate risks, and enhance client engagement while delivering high-quality designs.

Wattalps

Series A in 2024
Wattalps specializes in developing lithium power systems aimed at providing affordable battery solutions for small and medium series applications. The company's products prioritize passive safety, cooling efficiency, long life, and cell protection, facilitating the integration of these systems into vehicles and charging stations. With a focus on creating standard and modular designs, Wattalps aims to simplify installation processes, making them both fast and cost-effective. By advancing these technologies, the company contributes to the broader adoption of electric vehicles and sustainable transportation solutions.

Oryl Photonics

Grant in 2024
Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

MediWound

Grant in 2024
MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

Endoron Medical

Series A in 2024
Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

Innatera

Series A in 2024
Innatera is an innovative developer of ultra-low power neuromorphic processors designed to enhance the efficiency of sensor data processing. Established in 2018 as a spin-off from the Delft University of Technology, the company focuses on creating processors that replicate the brain's mechanisms for sensory perception. Utilizing a novel continuous-time analog-mixed signal processing architecture, Innatera's chips can process sensor data up to 100 times faster while consuming up to 500 times less energy compared to traditional processors. This technology enables businesses to access and analyze sensor data more effectively, positioning Innatera as a leader in the field of energy-efficient computing solutions.

Qblox

Series A in 2024
Qblox is a Dutch scaleup focused on quantum technology, specializing in the development of control hardware for quantum computers. The company offers patented, modular control systems that integrate hardware and software solutions designed to enhance the management of qubits. By creating a distributed processor architecture, Qblox simplifies experimental setups while improving gate fidelities through advanced electronics that reduce noise and drift. This innovation enables scientists to minimize crosstalk, implement low-latency control flows, and optimize measurement efficiency, addressing significant scientific and engineering challenges in the evolution of quantum computing. Qblox aims to support the transition from prototype quantum computers to powerful computational systems, thereby contributing to the broader advancement of quantum technology.

Bank of Memories

Grant in 2024
Bank of Memories operates a digital platform for long-term preservation of personal data, enabling users to store and organize various forms of digital memories, such as photos, videos, and documents. The platform employs blockchain technology and decentralized storage to ensure data security and longevity, allowing individuals and families to pass on their memories across generations. It offers features like dedicated data rooms for secure storage, an explorer tool for navigating stored information, and a whitepaper detailing the platform's technology.

King's College London

Grant in 2024
King's College London (informally King's or KCL) is a public research university located in London, United Kingdom, and a constituent college of the federal University of London. King's is arguably the third-oldest university in England, having been founded by King George IV and the Duke of Wellington in 1829, receiving its royal charter in the same year. St Thomas' Hospital, which is now a teaching hospital of King's College London School of Medicine, has roots dating back to 1173. In 1836, King's became one of the two founding colleges of the University of London. King's is based in the centre of London and organised into nine academic schools, spread across four Thames-side campuses in central London and another in Denmark Hill in south London. It is one of the largest centres for graduate and post-graduate medical teaching and biomedical research in Europe; it is home to six Medical Research Council centres for <a href="https://www.dissertationcorp.co.uk/">dissertation help</a> , the most of any British university, and is a founding member of the King's Health Partners academic health sciences centre. King's has around 25,000 students and 6,113 staff and had a total income of £587 million in 2012/13, of which £164 million was from research grants and contracts. King's is a world-leading university, currently ranked 19th in the world (6th in the UK and 8th in Europe) in the 2013 QS World University Rankings, and 38th in the world (6th in the UK and 9th in Europe) in the 2013 Times Higher Education World University Rankings. There are currently 12 Nobel Prize laureates amongst King's alumni and current and former faculty. King's is a member of the Association of Commonwealth Universities, the European University Association, the Russell Group and Universities UK. It forms part of the 'golden triangle' of British universities.

ProFuse Technology

Grant in 2024
ProFuse Technology specializes in advancing cultured meat production by enhancing methods and efficiency. The company has developed innovative technology that significantly reduces production time while improving meat quality and increasing yields. By accelerating muscle fiber growth, ProFuse enables meat producers to enhance their production capacity and lower costs, making cultured meat more accessible and sustainable.

Riverlane

Grant in 2024
Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Vitestro

Grant in 2024
Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Vitestro

Series A in 2024
Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

DRONAMICS

Grant in 2024
Dronamics is a developer of advanced unmanned aerial systems aimed at transforming airfreight logistics. By creating a new type of small, unmanned cargo airplane that is highly fuel-efficient, Dronamics aims to democratize shipping in emerging markets. The aircraft can transport payloads of 350 kilograms over distances of 2,500 kilometers at costs significantly lower than traditional air transport, reducing shipping expenses by over 50%. Designed for autonomous flight, the aircraft can be remotely monitored and managed via satellite, making it suitable for challenging delivery scenarios, including remote and mountainous regions. As the first and only Strategic Partner for drones recognized by IATA, Dronamics is positioned to make a substantial impact in the commercial logistics sector.

RS Research

Grant in 2024
RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for targeted cancer therapies. Founded in 2015, the company has established a proprietary drug delivery platform, Sagitta®, which enables the design of targeted drug candidates for various indications. RS Research's pipeline includes several proprietary programs in different stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. In addition to drug development, RS Research offers a range of services, including preclinical absorption, distribution, metabolism, and excretion studies, bioanalytical and analytical testing, and patent consulting. The company operates a GMP-certified production facility for clinical batch drug candidates and has successfully engaged in co-development projects with international partners, showcasing its commitment to advancing cancer treatment through modern therapeutic approaches.

Multiverse Computing

Series A in 2024
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Founded in 2019, the company specializes in creating quantum computing software that addresses complex financial and macro-economic challenges. Its products are tailored for various applications, including portfolio optimization, risk analysis, and market simulation. By leveraging probabilistic and nondeterministic technologies, Multiverse Computing aims to help organizations across diverse sectors such as banking, energy, manufacturing, and logistics navigate the complexities of the second quantum revolution, ultimately providing them with a competitive advantage in their respective industries.

Smart Farm Robotix

Grant in 2024
Smart Farm Robotix specializes in manufacturing agricultural robots that tackle the challenges of manual weeding, herbicide use, and machine weeding. Their robots provide a cost-effective, reliable, and fully automated solution, equipped with innovative weed detection and elimination technology. This enables farmers to cultivate crops more efficiently and sustainably, while reducing dependence on manual labor and harmful chemicals.

FreezeM

Series A in 2024
FreezeM is focused on advancing preservation technologies that enhance the use of insects as a sustainable protein source for the animal feed industry. The company is developing innovative methods for large-scale freezing of insects, which will facilitate the creation of global stocks of frozen insect neonates and eggs. This approach aims to address critical challenges related to the availability, cost, and regulatory hurdles associated with utilizing insects in animal feed. By ensuring a stable and year-round production of these beneficial insects, FreezeM seeks to make a significant impact on the animal feed market, while also contributing to biological pest control and species preservation.

Daze

Series A in 2024
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Brite Solar

Series A in 2024
Brite Solar is a nanomaterials company focused on developing advanced transparent solar glass technologies primarily for greenhouse and building applications. The company utilizes innovative materials and deposition techniques to create glass panels that can generate electricity through Die Sensitized Solar Cells (DSSC). This solar glass allows greenhouses to produce the energy needed to sustain their internal environments, significantly reducing their reliance on external electricity and lowering operating costs by approximately 28%. Additionally, Brite Solar's technology, which involves ink-jet printing nano-materials onto glass, simplifies the production process compared to traditional solar panels, making it more cost-effective. In the future, the company plans to expand its technology to include auto-dimming glass and architectural glass for building construction, further contributing to energy efficiency and sustainability in the built environment.

Aldoria

Series A in 2024
Aldoria specializes in space situational awareness, focusing on the collection, processing, and utilization of data to protect critical assets in space. The company addresses the growing challenges of space sustainability caused by increasing amounts of space debris and traffic. Its services encompass the detection, tracking, cataloging, and risk assessment of artificial satellites and space debris. By actively monitoring these elements, Aldoria helps operators and space organizations avoid potential hazards and adjust orbital paths, ultimately contributing to safer and more sustainable space operations. The company also provides users with a modern situational awareness platform and detailed sustainability reports.

Wavess

Grant in 2024
Wavess is an innovative predictive marketing analytics platform that utilizes advanced AI technologies to help businesses forecast the success of their marketing campaigns prior to launch. The platform combines AI algorithms with behavioral science to offer personalized recommendations, ultimately enhancing engagement and conversion rates. Targeting digital marketing agencies, scale-ups, and enterprises in sectors such as fintech, retail, and technology, Wavess provides critical insights into audience preferences and effective customer segmentation. Its distinctive features, including pre-launch prediction and ideal customer profiling, are designed to optimize campaign outcomes and facilitate tailored marketing strategies. In addition, the platform analyzes audience demographics and campaign seasonality to create customized posting schedules and identify valuable leads within a company's network, further improving overall campaign performance.

NETRIS Pharma

Series A in 2023
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Lotus Microsystems

Series A in 2023
Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug and play solutions enable our customers to innovate their electronics without worrying about power supply units.

respiQ

Grant in 2023
RespiQ is a healthtech startup that specializes in portable, non-invasive breath analysis technology aimed at the early detection and management of respiratory diseases. By utilizing advanced emission spectroscopy and artificial intelligence, RespiQ's device identifies volatile organic compounds (VOCs) in breath, enabling real-time detection of conditions such as COPD exacerbations. The company's focus on affordability, portability, and user-friendliness seeks to democratize access to advanced diagnostics, ultimately improving patient outcomes and reducing healthcare costs. In addition to respiratory diseases, RespiQ's versatile platform has potential applications for asthma, lung cancer, and infectious diseases. The company also offers an app that provides personalized health insights and dietary guidance, allowing users to monitor their health proactively. RespiQ's combination of technical and healthcare expertise positions it as a leader in breath diagnostics, with a commitment to enhancing overall health and well-being.

Efenco

Grant in 2023
Efenco is a cleantech startup focused on enhancing the energy conversion efficiency of industrial furnaces and boilers while minimizing their carbon emissions. The company has developed a patented product known as the high-energy ray ceramic chip (HERC), which can reduce carbon dioxide emissions and fuel costs by at least 18% across various energy-intensive sectors, including electricity generation, steel manufacturing, and cement production. Efenco employs principles from quantum and plasma physics, nanotechnology, and electrochemistry to revolutionize the management of waste heat generated from natural gas combustion. By converting waste heat into ionizing radiation through low-temperature plasma generation, Efenco provides industries with innovative solutions to optimize energy usage and improve thermal conversion efficiency, contributing to a more sustainable industrial landscape.

NEOGAP Therapeutics

Grant in 2023
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ACORAI

Grant in 2023
Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Skytree

Grant in 2023
Skytree is a company focused on developing innovative solutions for carbon dioxide capture and recycling. Founded in 2014, it leverages over a decade of research originally aimed at addressing CO2 challenges for astronauts on the International Space Station. Skytree specializes in direct air capture (DAC) technology that efficiently extracts carbon dioxide from ambient air. This technology supports a circular carbon supply, enabling businesses that need CO2 for their operations to reduce reliance on fossil fuels. By providing a reliable source of usable carbon dioxide, Skytree contributes to the transition toward a more sustainable future and a healthier planet. The company boasts a diverse team of skilled scientists, engineers, and business professionals, all guided by an experienced management team.

ResoTher Pharma

Grant in 2023
ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

RAIKU Packaging

Grant in 2023
RAIKU is a cleantech startup that produces 100% natural packaging material that has also great looks and shock absorption - most importantly, it gives 15-20 times more volume to its raw material making it one of the most resource efficient material uses in the world with high margins. Both the production is and products are clean making no harm to nature. RAIKU has raised over 1.2mln€ in the pre-seed stage, built a team of over 10 people, its own IP and clients are already using its packaging material. This material will up-end the 1 trillion € packaging sector.

SolasCure

Grant in 2023
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

VSORA

Grant in 2023
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

FarmInsect

Series A in 2023
FarmInsect GmbH, founded in 2019 and based in Bergkirchen, Germany, specializes in automated insect breeding systems designed to provide a sustainable and efficient source of animal feed. The company focuses on enabling local farmers to produce insect larvae from organic residues, which can be used as protein feed for livestock such as chickens, pigs, and fish. By offering a solution that replaces imported soy and fishmeal with locally sourced insect protein, FarmInsect aims to enhance the sustainability of animal husbandry while ensuring that farmers have a consistent supply of young larvae each week for their feeding needs.

PASQAL

Grant in 2023
Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

PrediSurge

Series A in 2023
PrediSurge is a software company that offers design and support solutions for physicians and medical device companies.

Kern Tec

Series A in 2023
Kern Tec specializes in upcycling fruit kernels from stone fruits, specifically cherries, apricots, and plums, to create innovative food products. The company refines these kernels into high-quality raw materials suitable for various applications, including baking ingredients, sustainable cosmetic oils, fertilizers, and biomass. By focusing on environmentally friendly processes, Kern Tec provides clients in the baking, food supplement, dairy alternatives, and confectionery industries with naturally sourced materials, promoting sustainability while meeting industry demands.

Swisspod Technologies

Grant in 2023
Swisspod Technologies SA is a transport development firm based in Monthey, Switzerland, founded in 2019. The company focuses on designing and developing Hyperloop vessels, which are tube-based transportation systems aimed at providing sustainable and efficient high-speed travel. Swisspod leverages high-quality Swiss engineering to create fully-electric Hyperloop pods that promise scalable and rapid transit between distant cities. The firm emphasizes energy efficiency and economic viability in its innovations, making its capsules both affordable and environmentally friendly. With a team of multidisciplinary experts, Swisspod is dedicated to transforming high-speed travel through its cutting-edge technology.

UPMEM

Grant in 2023
UPMEM is a fabless semiconductor company focused on enhancing the performance of data-intensive algorithms through its innovative Processing-In-Memory (PIM) solution. This technology addresses the limitations of traditional server architectures, which are hindered by data movement inefficiencies. By deploying a large number of programmable co-processors close to the data, UPMEM's platform accelerates performance for analytics and artificial intelligence applications by more than ten times. This unique approach not only improves computational speed but also reduces energy consumption and hardware footprint in data centers, making it an attractive solution for major application developers and cloud service providers.

Bound4Blue

Series A in 2023
bound4blue specializes in the development of innovative foldable and autonomous wingsail systems designed for integration into a variety of vessels. This technology serves as a complementary propulsion system, harnessing wind power to generate thrust and significantly reducing the reliance on main engine power. As a result, bound4blue's wingsails can lead to reductions in fuel consumption and pollutant emissions by up to 40%. In addition to improving environmental sustainability, the system offers a payback period of less than five years, making it an economically viable option for boat operators. The technology also facilitates the production of hydrogen and oxygen through the electrolysis of seawater, further enhancing its eco-friendly credentials.

Paptic

Series A in 2023
Paptic is a manufacturing company focused on creating innovative, wood-based materials that serve as sustainable alternatives to traditional paper and plastic products. By developing renewable and recyclable bags, Paptic addresses the pressing issue of plastic waste accumulation in the environment. The company’s products combine the eco-friendly properties of paper with the practical functionality of plastics, allowing customers to meet their everyday needs while contributing to a more sustainable environment.

INBRAIN Neuroelectronics

Grant in 2023
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

STABL

Venture Round in 2023
Stabl Energy is a developer focused on enhancing battery storage systems through innovative technology. The company creates virtual battery inverters that facilitate the integration of energy storage with renewable energy sources. By manufacturing central inverters that connect to the power grid, Stabl Energy aims to minimize self-consumption of battery storage, addressing challenges such as high battery voltage and enabling clients to fully utilize their battery capacity. This approach not only maximizes energy efficiency but also sets a new standard for the deployment of energy storage solutions in the renewable energy sector.

Pulse

Grant in 2023
Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Wooptix

Grant in 2023
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

ELGAN Pharma

Grant in 2023
Elgan Pharma is a biotechnology company specializing in neonatology, dedicated to addressing medical challenges and developmental issues faced by premature infants. The company is focused on developing innovative therapies utilizing nanotechnology to prevent visual impairment, a common and multifactorial problem in preterm babies. By targeting the specific needs of this vulnerable population, Elgan Pharma aims to enhance visual outcomes and reduce the risk of significant disabilities, ultimately supporting healthcare professionals in their efforts to improve the quality of life for these infants.

Aviwell

Grant in 2023
Aviwell is focused on creating healthy, natural, and sustainable solutions aimed at enhancing animal health and growth, thereby contributing to global nourishment. The company operates a microbiota-based discovery platform that leverages artificial intelligence and machine learning to bridge digital and life sciences. By developing innovative food products, Aviwell seeks to provide valuable insights into animal health, growth, and performance, ultimately supporting the agri-food industry in its efforts to sustainably meet the needs of a growing population.

Twinsity

Grant in 2023
Twinsity provides a platform designed for visualizing and inspecting high-resolution drone data and digital twins, facilitating collaboration throughout the infrastructure inspection process. The company's software integrates a comprehensive image database, enabling stakeholders to communicate, document, and inspect structures and assets more efficiently. By centralizing all relevant information, Twinsity enhances the management of infrastructure lifecycles and supports improved decision-making with the aid of artificial intelligence.

Cellbox Solutions

Grant in 2023
Cellbox Solutions is a technology company that specializes in innovative logistical solutions for the global BioMed industry. The company has developed a carbon dioxide incubator aimed at enhancing the storage, isolation, handling, and analysis of biological materials. This incubator supports the proper management of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the safe transport of living cells via roads, rails, or airways, Cellbox Solutions assists healthcare providers in their efforts to deliver advanced therapies and improve patient treatment outcomes.

Woodio

Grant in 2023
Woodio is a design-oriented company that specializes in innovative material technology for bathroom applications. The firm has developed a fully waterproof wood composite made from real wood chips, allowing for a range of design options while prioritizing sustainability. This technology offers customers fully recyclable biomaterials, enabling them to enhance and redesign their bathrooms with eco-friendly solutions. Woodio's focus on combining aesthetics with functionality positions it as a unique player in the market for bathroom design materials.

EBAMed

Series A in 2023
EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Escala Medical

Grant in 2023
Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

TreaTech

Series A in 2023
TreaTech is a Swiss Cleantech company founded in 2015 by engineers from the École Polytechnique Fédérale de Lausanne (EPFL). The company focuses on developing innovative treatment technology aimed at addressing the challenges of wastewater management. Its catalytic hydrothermal gasification (HTG) system provides an eco-friendly solution for the disposal of various liquid wastes, such as sewage sludge, which are typically incinerated or sent to landfills. This advanced thermochemical process transforms these wastes into valuable by-products, including renewable gas, clean water, and mineral salts that can be further upgraded into fertilizers. TreaTech's approach aligns with sustainable development goals and the principles of a circular economy, enabling clients to benefit from efficient wastewater treatment while recycling essential resources.

DTE ehf

Series A in 2023
DTE introduces breakthrough real-time process control analytics for metals production and processing towards Industry 4.0, through our robotic hardware and software solutions, automating current manual sampling processes for improved quality, cost, efficiency and safety.

Sensoneo

Series A in 2023
Sensoneo is a provider of advanced smart waste management solutions that assist cities and businesses in managing waste more efficiently and sustainably. The company utilizes proprietary ultrasonic sensors to monitor waste levels in real-time, coupled with sophisticated software that facilitates data-driven decision-making and optimizes waste collection processes. This technology enables significant reductions in waste collection costs, with improvements in operational efficiency and a potential decrease in carbon emissions. Sensoneo's solutions have been implemented in various locations across Europe, North America, South America, the Middle East, Australia, and New Zealand, attracting a diverse range of clients seeking to enhance their waste management practices. By automating the waste lifecycle and promoting eco-friendly initiatives, Sensoneo aims to transform traditional waste management into a more transparent and responsible process.

Cupffee

Grant in 2023
Cupffee specializes in the production of edible and biodegradable coffee cups and stirrers, offering a sustainable alternative to traditional disposable cups. Their manufacturing process is environmentally friendly, generating no industrial waste and only producing clean steam along with the pleasant aroma of freshly baked cookies. Additionally, any leftover materials from the cup production are repurposed as ingredients for other edible products, further enhancing their commitment to sustainability. Unlike conventional disposable cups, Cupffee's products decompose within days, allowing consumers to dispose of them in an environmentally responsible manner.

VCG.AI

Grant in 2023
The Intelligence Behind Global Circularity VCG.AI transforms industrial by-products and waste into valuable resources. AI-powered development of circular economy business models with the latest technology, material, market, and regulatory insights. Their proprietary AI solution, the Value Chain Generator®, helps companies, cities, and regions accelerate the transition to a circular economy, through Valorisation of By-products and Waste, Circular Product Development, Regional Circular Opportunities Assessment. When organisations want to better valorise by-products and waste, develop or source circular materials, or enhance circularity in their value chains, VCG.AI analyses thousands of data points to deliver the optimal solution tailored to their specific needs and locations. What once took months or years can now be achieved in just weeks—without the need to hire additional technology or bioeconomy experts. VCG.AI’s ever-expanding system includes: - 650+ validated circular solutions - 150+ different proven valorisation technologies - 3.5 M companies - 4M tons of project-ready organic residuals across Europe VCG.AI is on a mission to accelerate the transition to a circular economy by unlocking circular opportunities for businesses worldwide. Learn more about them at www.vcg.ai.

3DSecret

Grant in 2023
3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Agurotech

Grant in 2023
Agurotech specializes in developing soil sensing technology designed to enhance agricultural practices. The company's offerings include reliable sensing devices and tailored irrigation recommendations that help farmers optimize water usage and nutrients. By leveraging Internet of Things applications, Agurotech enables data-driven farming, allowing agricultural and horticultural producers to improve decision-making and increase productivity. Their focus on continuous improvement in the irrigation process aims to save natural resources while providing farmers with actionable insights for more effective resource management.

Inobiostar

Grant in 2023
Inobiostar focuses on research and experimental development services.

Norbite

Grant in 2023
Norbite is a biotech research firm focused on converting plastic waste into sustainable products through an innovative insect-based biorefinery. The company's technology integrates biorefinery and vertical farming methods to process plastic waste, yielding larvae that are bio-refined into proteins suitable for food and feed applications. By offering sustainable solutions, Norbite aims to contribute positively to environmental efforts while providing clients with valuable products and services.

EyeLights

Series A in 2023
EyeLights specializes in innovative motorcycle accessories by offering a Head Up Display GPS that enhances rider safety and experience. This device projects crucial navigation and safety information directly into the rider's line of sight, allowing them to maintain focus on the road. It alerts users to potential hazards such as dangerous bends, nearby obstacles, and speed limit violations. Designed for quick installation on various types of helmets, the EyeLights product can be set up in under five minutes. Its compact optical technology ensures visibility of GPS data from over two meters away and supports audio functions for up to eight hours. The device is adaptable to sun visors, resistant to rain and fog, and lightweight, weighing less than 100 grams, making it a practical choice for motorcycle enthusiasts seeking enhanced situational awareness while riding.

Naco

Grant in 2023
Naco Technologies Ltd, established in 2009 and headquartered in Riga, Latvia, specializes in the development, manufacturing, and supply of nano-coating technologies. The company offers a range of high-performance, multilayer and multicomponent coatings designed to enhance the durability and efficiency of equipment across various industries, including tooling, automotive, aerospace, and micro-chip manufacturing. These coatings, which include oil-enhanced, wear-protective, thermal barrier, and liquid-repellent varieties, are applied to client-supplied parts, creating ready-to-use coated components. In 2015, Naco Technologies was acquired by the Germany-based Schaeffler Group, further expanding its global reach and resources.

Samplix

Grant in 2023
Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Nemysis

Grant in 2023
Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Smart Immune

Grant in 2023
Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

inbiome

Grant in 2023
Inbiome is a biotechnology company specializing in molecular diagnostics. It has developed proprietary molecular culture technology that accelerates bacterial testing and microbiome analysis. The company aims to advance clinical microbiology by focusing on microbial detection and product development, enabling more accurate and timely diagnoses, and ultimately improving patient outcomes.

Quantune Technologies

Grant in 2023
Quantune is a deep tech startup specializing in optics and photonics technology. The company develops a compact infrared spectrometer that miniaturizes traditional laboratory equipment for molecular analysis, making it accessible for both biomedical consumer devices and industrial applications. This innovative spectrometer facilitates continuous and non-invasive health monitoring, allowing clients to achieve real-time monitoring and analysis of chemical compounds and emissions. By transforming large-scale laboratory processes into a portable module, Quantune enables novel applications in various fields, enhancing the capabilities of health and environmental monitoring.

Miwa

Grant in 2023
Miwa is a retail solution provider focused on minimizing single-use packaging through a circular economy strategy. The company offers a system that includes reusable containers designed to reduce waste and promote sustainability. These sealable and reusable containers work alongside electronic dispensers located in retail environments, facilitating the bulk distribution of both food and non-food products. By enabling producers and retailers to store and dispense items in a hygienic manner, Miwa aims to create a more efficient and environmentally friendly approach to retail.

Molecular Attraction

Grant in 2023
Molecular Attraction is a research and development firm focused on creating innovative solutions for vector-borne disease control and eradication. The company specializes in identifying biological compounds that can modify the behavior of vector organisms, including mosquitoes, ticks, flies, and rodents. By utilizing sustainable technology and chemical blends, Molecular Attraction aims to provide effective, long-lasting, and low-maintenance strategies for managing pest populations. Their approach not only enhances the effectiveness of pest control measures but also promotes environmentally friendly practices, contributing to a more cost-effective solution for combating vector-borne diseases.

GrayMatters Health

Grant in 2023
GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.

Qurv

Grant in 2023
Qurv, established in 2020, specializes in developing advanced image sensor technologies and integrated solutions. The company's core business is enabling next-generation computer vision applications, catering to the growing demands of autonomous and intelligent systems. Qurv's innovative technology, built on over eight years of research, leverages current CMOS manufacturing and advanced materials to deliver high-performance, reliable, and functional solutions for XR devices, service robots, and automotive industries.

Sunrise

Series A in 2023
Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

IDloop

Grant in 2023
IDloop specializes in biometric technology, focusing on contactless fingerprint sensor solutions tailored for both business and government markets. The company’s innovative technology captures secure three-dimensional images of multiple fingers, which significantly reduces false acceptance rates and enhances overall security. By leveraging advanced 3D imaging, artificial intelligence, and embedded technology, IDloop aims to provide efficient and reliable biometric identification, addressing the growing demand for secure access solutions in various sectors.

Valo Therapeutics

Grant in 2023
Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.